Therapeutic efficiency of Atosiban an oxytocin receptor blocking agent in the treatment of experimental endometriosis

Basit Öğe Kaydı
dc.authorid111548en_US
dc.authorid181316en_US
dc.authorid9712en_US
dc.authorid13321en_US
dc.contributor.authorŞimşek, Yavuz
dc.contributor.authorÇelik, Önder
dc.contributor.authorKaraer, Abdullah
dc.contributor.authorGül, Mehmet
dc.contributor.authorYılmaz, Ercan
dc.contributor.authorKoç, Önder
dc.contributor.authorÇolak, Cemil
dc.contributor.authorZengin, Şehnaz
dc.contributor.authorAydın, Nasuhi Engin
dc.date.accessioned2017-12-27T08:14:59Z
dc.date.available2017-12-27T08:14:59Z
dc.date.issued2012
dc.departmentİnönü Üniversitesien_US
dc.descriptionArch Gynecol Obstet (2012) 286:777–783.en_US
dc.description.abstractPurpose The current study investigated the potential therapeutic efficiency of atosiban, an oxytocin receptor antagonist, in an experimental endometriosis model. Methods Endometriosis was surgically induced in 35 female rats during estrus. Four weeks after this procedure, relaparotomy was performed. The viability and dimensions of the endometriosis foci were recorded. Rats were then randomly divided into three groups. In the first group (n = 8), a daily dose of 0.2 ml 0.9 % NaCl was injected intraperitoneally (i.p.) (control cases). In the second and third groups (n = 8 and n = 8), 0.5 mg/kg/day i.p. atosiban and 1 mg/day i.p. diltiazem were given, respectively. At the end of the treatment, laparotomy was performed, and the dimensions of the endometriosis foci were recorded. The endometrial implants were processed for histological and immunohistochemical studies. The volumes of endometriotic implants were measured, and immunohistochemical analyses were performed, and compared between the groups. Results After the treatment with atosiban, volumes of endometriotic implants decreased significantly. Proliferating cell nuclear antigen expression levels were significantly reduced in the atosiban and diltiazem groups compared with the control group. Conclusions In a rat endometriosis model, atosiban, an agent used for the first time for the medical treatment of endometriosis, has shown significant therapeutic efficiency.en_US
dc.identifier.citationSimsek, Y., Celik, O., Karaer, A., Gul, M., Yılmaz, E., Koc, O., Colak, C., Zengin, S., Aydin Nasuhi, E., (2012). Therapeutic efficiency of Atosiban an oxytocin receptor blocking agent in the treatment of experimental endometriosis. Arch Gynecol Obstet (2012) 286:777–783en_US
dc.identifier.doi10.1007/s00404-012-2390-7en_US
dc.identifier.endpage783en_US
dc.identifier.issue0en_US
dc.identifier.startpage777en_US
dc.identifier.urihttps://link.springer.com/content/pdf/10.1007%2Fs00404-012-2390-7.pdf
dc.identifier.urihttps://hdl.handle.net/11616/7935
dc.identifier.volume286en_US
dc.language.isoenen_US
dc.publisherArchives of Gynecology and Obstetricsen_US
dc.relation.ispartofArchives of Gynecology and Obstetricsen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectEndometriosisen_US
dc.subjectReceptorsen_US
dc.subjectOxytocinen_US
dc.subjectAtosibanen_US
dc.subjectTherapyen_US
dc.titleTherapeutic efficiency of Atosiban an oxytocin receptor blocking agent in the treatment of experimental endometriosisen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Makale Dosyası.pdf
Boyut:
400.31 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.71 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Tıp Fakültesi, Biyoistatistik ve Tıp Bilişimi Anabilim Dalı Koleksiyonu